Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate - Slideshow

Invivyd presented updates on its REVOLUTION clinical program, highlighting progress in developing monoclonal antibody therapies targeting infectious diseases during an April 2026 investor event. The company emphasized advancements in its measles monoclonal antibody candidate, positioning it as a potential breakthrough for prevention and treatment amid rising global measles cases. Clinical trial data shared in the slideshow suggests accelerated development timelines, with regulatory submissions anticipated within 12–18 months pending positive Phase 2/3 results. Invivyd’s pipeline expansion includes next-gen antibody platforms leveraging proprietary technology to enhance durability and broad-spectrum efficacy against viral mutations. Investors were briefed on strategic partnerships and manufacturing scale-up plans to support commercialization, underscoring the company’s focus on rapid deployment post-approval.